دورية
SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas
| العنوان: | SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas |
|---|---|
| المؤلفون: | Hamblett, Kevin J., Cochran, Julia, Snead, Katie, Jin, Steven, Yumul, Roma, Simmons, Jessica, Stone, Ivan, Lyski, Ryan, Schrum, Jason P., Lim, Andrea R., Clarke, Astrid |
| المصدر: | Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p1440-1440, 1p |
| مستخلص: | SGN-35C is an antibody drug conjugate composed of an anti-CD30 antibody conjugated to a camptothecin-derived topoisomerase 1 (TOP1) inhibitor payload. SGN-35C was designed to leverage the antibody backbone from brentuximab vedotin (BV) and the novel mechanism of action of camptothecin-derived ADCs. Here, we evaluated the mechanism of action, cytotoxicity, and safety in in vitro and in vivo models. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2023-182400 |